IL6 and acute coronary syndrome: As demonstrated in several clinical trials, targeting inflammation can reduce very high residual cardiovascular risk in patients with acute coronary syndromes or stroke.5 More recently, the RESCUE trial reported reduced biomarkers of inflammation and thrombosis in high cardiovascular risk patients treated with the anti–IL-6 mAb ziltivekimab.